{"id":"W4309827972","doi":"10.1001/jamaoncol.2022.5486","title":"Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Quality of life (healthcare); Clinical endpoint; Oncology; Randomized controlled trial; Randomization; Clinical trial; Adjuvant therapy; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234144,0.0004527011,0.00103017,0.0002453381,0.0002137236,0.0005372036,0.0003991267,0.0005680889,0.00180048],"category_scores_gemma":[0.002564376,0.000229711,0.002122195,0.0002247016,0.0003435546,0.0006267916,0.0002874334,0.001254481,0.0001760381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008361469,"about_ca_system_score_gemma":0.000890488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007975742,"about_ca_topic_score_gemma":0.00222779,"domain_scores_codex":[0.9991955,0.0005270139,0.0000625042,0.0000766174,0.000066977,0.00007138258],"domain_scores_gemma":[0.9988226,0.0004586399,0.0003496725,0.00007374393,0.00004711251,0.0002480969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8841699,0.009007816,0.01957804,0.0005791967,0.003146009,0.0000389849,0.00007755979,0.001549692,0.002776784,0.00009031385,0.0008331484,0.07815254],"study_design_scores_gemma":[0.4520292,0.4081948,0.1251843,0.0002723361,0.005720312,0.000145809,0.0001121437,0.003999176,0.002153737,0.0005388975,0.001597158,0.00005216635],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942075,0.004412964,0.00009703646,0.0002145772,0.00007121907,0.0002293391,0.0001991365,0.000008986511,0.0005591605],"genre_scores_gemma":[0.9981709,0.0006940429,0.0002024978,0.0002065185,0.0000605904,0.0002478392,0.0002314298,0.000002010398,0.0001841976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00234144,"threshold_uncertainty_score":0.01238286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02678739375407324,"score_gpt":0.33753905426309,"score_spread":0.3107516605090168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}